0001104659-24-067223.txt : 20240531 0001104659-24-067223.hdr.sgml : 20240531 20240531163038 ACCESSION NUMBER: 0001104659-24-067223 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240531 DATE AS OF CHANGE: 20240531 EFFECTIVENESS DATE: 20240531 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SEELOS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001017491 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 870449967 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-514857 FILM NUMBER: 241010256 BUSINESS ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646) 293-2100 MAIL ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: APRICUS BIOSCIENCES, INC. DATE OF NAME CHANGE: 20100914 FORMER COMPANY: FORMER CONFORMED NAME: NEXMED INC DATE OF NAME CHANGE: 19970311 D 1 primary_doc.xml X0708 D LIVE 0001017491 SEELOS THERAPEUTICS, INC. 300 PARK AVENUE 2ND FLOOR NEW YORK NY NEW YORK 10022 (646) 293-2100 NEVADA None APRICUS BIOSCIENCES, INC. NEXMED INC Corporation true Raj Mehra c/o Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York NY NEW YORK 10022 Executive Officer Director Brian Lian c/o Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York NY NEW YORK 10022 Director Richard W. Pascoe c/o Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York NY NEW YORK 10022 Director Margaret Dalesandro c/o Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York NY NEW YORK 10022 Director Michael Golembiewski c/o Seelos Therapeutics, Inc. 300 Park Avenue, 2nd Floor New York NY NEW YORK 10022 Executive Officer Biotechnology No Revenues 06b false 2024-05-21 false true true false 0 Roth Capital Partners, LLC 000015407 None None 888 San Clemente Drive Suite 400 Newport Beach CA CALIFORNIA 92660 NY NEW YORK false 2042954 0 2042954 Aggregate exercise price of warrants for 924,414 shares of common stock ($2.21/share), issued in connection with a registered direct offering of 380,968 shares of common stock and pre-funded warrants for 81,239 shares of common stock. false 2 79586 50000 $79,586.36 is for a fee of 7.0% of the gross proceeds from the sale of securities in the registered direct offering and concurrent private placement of warrants, and up to $50,000 is for the reimbursement of expenses incurred by the placement agent. 0 true SEELOS THERAPEUTICS, INC. /s/ Michael Golembiewski Michael Golembiewski Chief Financial officer 2024-05-31